Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Sitting SBP ≥140 mm Hg and \< 160 mmHg on one antihypertensive agen or~* Sitting SBP ≥ 150 mm Hg and \< 180 mm Hg on no antihypertensive treatment.~Exclusion Criteria:~* Congestive heart failure (clinically defined).~* Serum creatinine levels greater than 170 µmol/l or estimated glomerular filtration rate (eGFR) \< 30 ml/min.~* History of coronary heart disease (i.e., chronic stable angina, myocardial infarction or acute coronary syndrome).~* History of a stroke or other cerebrovascular accident (i.e. transient ischaemic attack or reversible ischaemic neurological deficit).~* Known or suspected secondary hypertension.~* Any other concomitant illness, physical or mental impairment that could interfere with the effective conduct of the study.~* Pregnancy or those of child-bearing age who are not taking reliable contraception.~* Patients with a history of intolerance to any of the study medications for example angioedema or dry cough with angiotensin converting enzyme inhibitors.~* Patients on maximum dose of any of the study medications as monotherapy (i.e. amlodipine 10 mg/day or hydrochlorothiazide 25 mg/day or perindopril 8 mg/day)~* Gout.~* Serum potassium \< 3.5mmol/L at screening.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Perindopril plus Amlodipine at a dose of 4mg/5mg once daily for two months and 8mg/10mg once daily for the remaining four months.
- 2 (Type: ACTIVE_COMPARATOR): Perindopril Plus Hydrochlorothiazide at a dose of 4mg/12.5mg and 8mg/25mg once daily for the remaining four months.
- 3 (Type: ACTIVE_COMPARATOR): Amlodipine plus Hydrochlorothiazide 5mg/12.5mg for two months and 10mg/25mg for the remaining four months.

Based on this trial design, predict the completion outcome and termination type (if applicable).